Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

A7861

Sigma-Aldrich

Asenapine maleate

≥98% (HPLC)

Synonyme(s) :

(3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12btetrahydro-1Hdibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-2-butenedioate, Org 5222, trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole maleate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C17H16ClNO ·C4H4O4
Numéro CAS:
Poids moléculaire :
401.84
Numéro CE :
Code UNSPSC :
12352200
ID de substance PubChem :
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

powder

Couleur

white to off-white

Solubilité

H2O: ≥10 mg/mL

Auteur

Merck & Co., Inc., Kenilworth, NJ, U.S.

Température de stockage

2-8°C

Chaîne SMILES 

OC(=O)\C=C/C(O)=O.CN1C[C@H]2[C@H](C1)c3cc(Cl)ccc3Oc4ccccc24

InChI

1S/C17H16ClNO.C4H4O4/c1-19-9-14-12-4-2-3-5-16(12)20-17-7-6-11(18)8-13(17)15(14)10-19;5-3(6)1-2-4(7)8/h2-8,14-15H,9-10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,15-;/m1./s1

Clé InChI

GMDCDXMAFMEDAG-CHHFXETESA-N

Description générale

Asenapine maleate acts as an antimanic. It belongs to the family of dibenzoxepinopyrrolidines. Asenapine is considered to be a weak inhibitor of cytochrome P450 2D6 (CYP2D6). It increases the level of dopamine, norepinephrine and acetylcholine in brain.

Application

Asenapine maleate has been used as a stressor in studying the Fos expression in forebrain structures of rat models.
Asenapine maleate is a serotonin 5-HT and dopamine D2 receptor antagonist. Asenapine maleate can be used to treat schizophrenia and bipolar mania.

Actions biochimiques/physiologiques

Asenapine maleate is a 5-HT receptor antagonist (5-HT1A,1B, 5-HT2A, 2B, 2C, 5-HT5A, 5-HT6 and 5-HT7), a D2 antagonist, and an antipsychotic.

Caractéristiques et avantages

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Skull and crossbonesEnvironment

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Acute Tox. 3 Oral - Aquatic Acute 1 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Jakub Trawiński et al.
Ecotoxicology and environmental safety, 162, 272-286 (2018-07-11)
The photolytic and photocatalytic transformation of an antipsychotic drug asenapine with the use of H2O2 and TiO2 was studied. A method employing irradiation with a simulated full solar spectrum in the photostability chamber was applied, then the reverse-phase ultra high
The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania
Tarazi FI and Neill JC
Expert Opinion on Drug Discovery, 8(1), 93-103 (2013)
Ahmed A Abu-Hassan et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 239, 118474-118474 (2020-05-26)
Asenapine maleate was approved by the FDA for the treatment of schizophrenia and mania or mixed episodes with bipolar I disorder. In the present article, two spectroscopic methods were developed and validated for the determination of asenapine. Both methods depend
Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania.
Tarazi FI and Shahid M
Drugs Today (Barc), 45(12), 865-876 (2009)
Frank I Tarazi et al.
Drugs of today (Barcelona, Spain : 1998), 45(12), 865-876 (2010-02-06)
Schizophrenia and bipolar disorder are serious neuropsychiatric disorders with substantial health risks for patients that result in major socioeconomic burdens on society. Current therapeutic agents fail to adequately address patient needs in terms of efficacy, tolerability and treatment-related adverse events.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique